GlassScriptPhysician profile
Christina Sweatt
NPI 1114570009
$1,741.78
in general payments reported to CMS, 2019-2025
23 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $266 · 2022: $384 · 2023: $326 · 2024: $330 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.77 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $375.19 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $249.77 | 2021-2025 | |
| Lilly USA, LLC | $186.97 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $125.04 | 2021-2025 | Airsupra |
| Pfizer INC. | $111.61 | 2022-2025 | |
| Astellas Pharma US INC | $99.99 | 2025 | |
| Glaxosmithkline, LLC. | $89.70 | 2022-2024 | Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $75.17 | 2022-2023 | Xtampza, Belbuca |
| Biohaven Pharmaceutical Holding Company LTD. | $60.81 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.25 | 2023 | Relistor |
| Abbott Laboratories | $38.91 | 2025 | Freestyle Libre 3 |
| Si-Bone, INC. | $38.81 | 2023 | |
| Ibsa Pharma INC. | $36.15 | 2022 | |
| Exact Sciences Corporation | $31.27 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $28.55 | 2021-2025 | Minimed 780g |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $27.74 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.74 | 2021 | |
| Valinor Pharma, LLC | $19.21 | 2024 | Movantik |
| Ipsen Biopharmaceuticals, INC | $17.80 | 2021 | |
| Amgen INC. | $17.69 | 2024 | Otezla, Repatha |
| Vertex Pharmaceuticals Incorporated | $15.64 | 2025 | |
| Amarin Pharma, INC. | $14.17 | 2022 | |
| Currax Pharmaceuticals LLC | $13.60 | 2024 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Sweatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.